Triiodothyronine alongside levothyroxine in the management of hypothyroidism?

被引:7
|
作者
Gottwald-Hostalek, Ulrike [1 ]
Kahaly, George J. [2 ]
机构
[1] Merck Healthcare KGaA, Frankfurterstr 250, D-64273 Darmstadt, Germany
[2] Johannes Gutenberg Univ Med Ctr, Dept Med 1, Mainz, Germany
关键词
Triiodothyronine; hypothyroidism; levothyroxine; combination therapy; THYROXINE PLUS TRIIODOTHYRONINE; QUALITY-OF-LIFE; COMBINATION THERAPY; REPLACEMENT THERAPY; DOUBLE-BLIND; TREATING HYPOTHYROIDISM; ATHYREOTIC PATIENTS; THYROID-FUNCTION; LIOTHYRONINE; 3,5,3'-TRIIODOTHYRONINE;
D O I
10.1080/03007995.2021.1984219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The current guideline-based management of hypothyroidism recommends monotherapy with levothyroxine (LT4), titrated to maintain the level of thyrotropin within a euthyroid reference range. This has been successful for most people with hypothyroidism, but a substantial minority still report symptoms of hypothyroidism unexplained by a comorbid medical condition. LT4 is essentially a prodrug for triiodothyronine (T3), the thyroid hormone that acts on target tissues in the brain and the periphery. Thyroid hormone replacement with LT4 alone does not restore physiological tissue levels of thyroid hormones, particularly T3. During the last two decades, much interest has focussed on the potential of combinations of LT4 and T3 to provide a superior outcome to LT4 monotherapy for people with hypothyroidism, especially those with residual symptoms despite thyrotropin-optimized LT4. This review seeks to provide an overview of currently available evidence on combination (LT4 + T3) therapy to be used for personalized medicine in patients with hypothyroidism. A number of randomized, controlled trials (RCTs) have failed to demonstrate superiority for the combination therapy approach, largely due to non-physiological T3 doses. However, patients with hypothyroidism are highly heterogeneous in terms of their residual thyroid function, individual set points for optimal thyroid homeostasis and for the presence or absence of polymorphisms in deiodinase enzymes in tissues that activate and deactivate circulating thyroid hormones. Accordingly, these RCTs may have failed to demonstrate benefits of combination therapy in individual hypothyroid phenotypes. The pharmacokinetics of LT4 and T3 also differ, which is a barrier to their co-administration. Future clinical trials using LT4 + T3 tablets better suited for combination therapy will resolve the outstanding research questions relating to the place of LT4 + T3 combination therapy in the management of hypothyroidism.
引用
收藏
页码:2099 / 2106
页数:8
相关论文
共 50 条
  • [41] Is Parenteral Levothyroxine Therapy Safe in Intractable Hypothyroidism?
    Peynirci, Hande
    Taskiran, Bengur
    Erturk, Erdinc
    Sisman, Pinar
    Ersoy, Canan
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2018, 110 (03) : 245 - 249
  • [42] Adherence to levothyroxine among patients with hypothyroidism in Lebanon
    El Helou, Sarah
    Hallit, Souheil
    Awada, Sanaa
    Al-Hajje, Amal
    Rachidi, Samar
    Bawab, Wafaa
    Salameh, Pascale
    Zein, Salam
    EASTERN MEDITERRANEAN HEALTH JOURNAL, 2019, 25 (03) : 149 - 159
  • [43] Levothyroxine for the Treatment of Subclinical Hypothyroidism and Cardiovascular Disease
    Sue, Laura Y.
    Leung, Angela M.
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [44] Effect of Levothyroxine Therapy on the Lipid Profile of Patients With Hypothyroidism: A Systematic Review
    Nishat, Samreen
    Mueka, Isaac N.
    Hassan, Maria U.
    Pandey, Ravi K.
    Lwin, Bo B.
    Vashishta, Apoorva
    Nassar, Sondos T.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (07)
  • [45] Systemic Thyroid Hormone Status During Levothyroxine Therapy in Hypothyroidism: A Systematic Review and Meta-Analysis
    McAninch, Elizabeth A.
    Rajan, Kumar B.
    Miller, Corinne H.
    Bianco, Antonio C.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2018, 103 (12) : 4533 - 4542
  • [46] The emergence of levothyroxine as a treatment for hypothyroidism
    James V. Hennessey
    Endocrine, 2017, 55 : 6 - 18
  • [47] Recommendations for treatment of hypothyroidism with levothyroxine and levotriiodothyronine: a 2016 position statement of the Italian Society of Endocrinology and the Italian Thyroid Association
    B. Biondi
    L. Bartalena
    L. Chiovato
    A. Lenzi
    S. Mariotti
    F. Pacini
    A. Pontecorvi
    P. Vitti
    F. Trimarchi
    Journal of Endocrinological Investigation, 2016, 39 : 1465 - 1474
  • [48] Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations
    Woeber, KA
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (02) : 106 - 109
  • [49] Levothyroxine therapy and serum free thyroxine and free triiodothyronine concentrations
    Kenneth A. Woeber
    Journal of Endocrinological Investigation, 2002, 25 : 106 - 109
  • [50] Clinical Efficacy and Pharmacokinetics of Levothyroxine Suppository in Patients with Hypothyroidism
    Kashiwagura, Yasuharu
    Uchida, Shinya
    Tanaka, Shimako
    Watanabe, Hiroshi
    Masuzawa, Masahiro
    Sasaki, Tadanori
    Namiki, Noriyuki
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2014, 37 (04) : 666 - 670